Apellis Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
01/08/2024 14:54
* Apellis Pharmaceuticals Inc APLS.OQ reported a quarterly
adjusted loss of 28 cents per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of $-1.02. The mean expectation of
seventeen analysts for the quarter was for a loss of 32 cents
per share. Wall Street expected results to range from -42 cents
to -9 cents per share.
* Revenue rose 110.3% to $199.69 million from a year ago;
analysts
expected $191.07 million.
* Apellis Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 30 cents.
* The company reported a quarterly loss of $37.66 million.
* Apellis Pharmaceuticals Inc shares had risen by 3.2% this
quarter and lost 33.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 11.6%
in the last three months.
* In the last 30 days, four analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Apellis
Pharmaceuticals Inc is $81.00
This summary was machine generated from LSEG data August 1 at
01:54 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.32 -0.28 Beat
Mar. 31 2024 -0.47 -0.42 Beat
Dec. 31 2023 -0.69 -0.73 Missed
Sep. 30 2023 -0.86 -1.17 Missed